GE Healthcare, the health business of General Electric, will dedicate $1 billion of its total R&D budget during the next five years to its technologies for manufacturing biopharmaceuticals and for cancer research. Part of the money will go toward expanding the company’s cancer-diagnostic and molecular-imaging capabilities, as well.
GE Healthcare’s planned investment will focus on developing new oncology solutions, will help develop technologies, and continue the company’s current research. The funds will be dedicated to the following projects:
The $1-billion investment involves all parts of GE Healthcare’s global business and is intended to help the company market promising cancer solutions. “The only way we can help clinicians beat cancer is to give them the tools to find it earlier, stage it better, and quantitatively measure response to therapy,” said GE Vice-President and GE Healthcare Chief Technology Officer Mike Harsh in a company press release. Harsh oversees GE Healthcare’s global R&D efforts. “The integration of GE Healthcare’s expertise in imaging, analytics, diagnostics, cellular analysis, and healthcare IT is helping create technologies and solutions that can be used in a rural developing country or in a modern urban hospital,” he added.
Data from the World Health Organization indicate that cancer rates could increase by 50%, which would create 15 million new cases of cancer in 2020. The potential increase in incidence around the world could make cancer a key global healthcare challenge.
See related Pharm Tech articles:
Global Healthcare on the Ground (Pharm Tech)
Big Pharma’s Manufacturing Blueprint for the Future (Pharm Tech)